To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Imago BioSciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Imago BioSciences, Inc. (“Imago” or the “Company”) (NASDAQ: IMGO), in connection with the tender offer for the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK).  Under the tender offer terms, the Company’s shareholders will receive $36.00 in cash for each share of Imago common stock owned.  The transaction is valued at $1.35 billion.

Weiss Law is investigating whether (i) Imago’s board of directors acted in the best interests of Company shareholders in agreeing to the tender offer, (ii) the $36.00 per-share merger consideration adequately compensates Imago’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.